Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 431

1.

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.

Psychopharmacology (Berl). 2007 Jun;192(3):441-8. Epub 2007 Feb 20.

PMID:
17310385
[PubMed - indexed for MEDLINE]
2.

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.

Am J Psychiatry. 2003 Feb;160(2):297-302.

PMID:
12562576
[PubMed - indexed for MEDLINE]
3.

Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A.

Psychopharmacology (Berl). 2013 Apr;226(3):615-22. doi: 10.1007/s00213-012-2935-2. Epub 2012 Dec 13.

PMID:
23239133
[PubMed - indexed for MEDLINE]
4.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
[PubMed - indexed for MEDLINE]
5.

Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.

Poyurovsky M, Faragian S, Fuchs C, Pashinian A.

Isr J Psychiatry Relat Sci. 2009;46(3):213-20.

PMID:
20039523
[PubMed - indexed for MEDLINE]
Free Article
6.

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A.

Eur Neuropsychopharmacol. 2004 Aug;14(4):332-6.

PMID:
15163444
[PubMed - indexed for MEDLINE]
7.

The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.

Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, Poyurovsky M.

Psychopharmacology (Berl). 2013 Nov;230(1):23-7. doi: 10.1007/s00213-013-3199-1. Epub 2013 Jul 5.

PMID:
23828160
[PubMed - indexed for MEDLINE]
8.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.

Am J Psychiatry. 2005 May;162(5):954-62.

PMID:
15863798
[PubMed - indexed for MEDLINE]
9.

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

Saddichha S, Ameen S, Akhtar S.

J Clin Psychopharmacol. 2008 Feb;28(1):27-31. doi: 10.1097/jcp.0b013e3181602fe6.

PMID:
18204337
[PubMed - indexed for MEDLINE]
10.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
[PubMed - indexed for MEDLINE]
11.

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A.

Am J Psychiatry. 2002 Jun;159(6):1058-60.

PMID:
12042201
[PubMed - indexed for MEDLINE]
12.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
[PubMed - indexed for MEDLINE]
13.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342
[PubMed - indexed for MEDLINE]
14.

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.

Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A.

Int Clin Psychopharmacol. 2005 Mar;20(2):101-3.

PMID:
15729086
[PubMed - indexed for MEDLINE]
15.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP.

Ann Clin Psychiatry. 2008 Apr-Jun;20(2):71-8. doi: 10.1080/10401230802017050.

PMID:
18568578
[PubMed - indexed for MEDLINE]
16.

Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.

Milano W, Grillo F, Del Mastro A, De Rosa M, Sanseverino B, Petrella C, Capasso A.

Adv Ther. 2007 Jan-Feb;24(1):123-34.

PMID:
17526469
[PubMed - indexed for MEDLINE]
17.

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.

Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B.

J Clin Psychiatry. 2006 Aug;67(8):1253-60.

PMID:
16965204
[PubMed - indexed for MEDLINE]
18.

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.

Assunção SS, Ruschel SI, Rosa Lde C, Campos JA, Alves MJ, Bracco OL, de Lima MS.

Rev Bras Psiquiatr. 2006 Dec;28(4):270-6. Erratum in: Rev Bras Psiquiatr. 2007 Mar;29(1):v.

PMID:
17242805
[PubMed - indexed for MEDLINE]
Free Article
19.

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.

Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.

J Clin Psychiatry. 2002 Jan;63(1):31-7.

PMID:
11838623
[PubMed - indexed for MEDLINE]
20.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25. doi: 10.3371/CSRP.5.1.3.

PMID:
21459735
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk